Treatment of pulmonary arterial hypertension (PAH) with oral endothelin-receptor antagonist bosentan in systemic sclerosis: BREATHE-1 trial and clinical experience

被引：0
|
作者：
Ahmadi-Simab, K
Lamprecht, P
Hellmisch, B
Gross, WL
机构：
[1] Univ Klinikum Schleswig Holstein, Poliklin Rheumatol, D-23538 Lubeck, Germany
[2] Rheumaklin Bad Bramstedt, D-23538 Lubeck, Germany
来源：
ZEITSCHRIFT FUR RHEUMATOLOGIE | 2004年 / 63卷 / 06期
关键词：
D O I：
10.1007/s00393-004-0594-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：495 / 497
页数：3
相关论文
共 50 条
  • [11] Treatment of severe pulmonary arterial hypertension related to systemic sclerosis: Experience with bosentan
    Ahmadi-Slmab, K
    Hellmich, B
    Gross, WL
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 294 - 294
  • [12] Experience with bosentan in pulmonary arterial hypertension secondary to systemic sclerosis
    Caroline Barranco
    Nature Clinical Practice Rheumatology, 2006, 2 (4): : 181 - 181
  • [13] BREATHE-1 results of a multicenter, randomized, double-blind, placebo-controlled study of bosentan in pulmonary arterial hypertension (PAH)
    Rubin, LJ
    Simonneaux, G
    Barst, RJ
    Gahe, N
    Badesch, DB
    Black, C
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S266 - S266
  • [14] Effects of the oral endothelin receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension
    Galie, N
    Hinderliter, AL
    Torbicki, A
    Simonneau, G
    Espinola-Zabaleta, N
    Rocchi, G
    Kurzyna, M
    Kronenberg, A
    Frantz, R
    Sherif, N
    Barst, R
    Dujardin, K
    Channick, R
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (05) : 224A - 224A
  • [15] Bosentan treatment in pulmonary arterial hypertension secondary to systemic sclerosis
    Piludu, G.
    Nalli, E.
    Amoresano, D.
    Farci, M.
    Muttini, T.
    D'Aietti, I
    Mura, N.
    Loddo, M.
    Giacco, G.
    ALLERGY, 2008, 63 : 353 - 353
  • [16] SYSTEMATIC EVALUATION OF GENETIC DETERMINANTS OF HEPATOTOXICITY FROM THE ENDOTHELIN RECEPTOR ANTAGONIST BOSENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH)
    Seyfarth, Hans-Juergen
    Favreau, Nadine
    Tennert, Carsten
    Rosendahl, Jonas
    Ruffert, Claudia
    Halank, Michael
    Wirtz, Hubert
    Moessner, Joachim
    Kovacs, Peter
    Wittenburg, Henning
    HEPATOLOGY, 2011, 54 : 530A - 531A
  • [17] Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience
    Belge, Catharina
    Delcroix, Marion
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2019, 13
  • [18] Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)
    Mitsakis, Periklis
    Yerly, Patrick
    Dunet, Vincent
    Deshayes, Emmanuel
    Aebsicher, Nicole
    Prella, Maura
    Prior, John
    Aubert, John-David
    Laurent, Nicod
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [19] Role of the endothelin receptor antagonist bosentan in the treatment of patients with pulmonary hypertension
    Tsareva, N. A.
    TERAPEVTICHESKII ARKHIV, 2013, 85 (12) : 127 - 136
  • [20] Effect of bosentan treatment on survival of patients with pulmonary arterial hypertension related to systemic sclerosis (PAH-SSc)
    Denton, CP
    Black, CM
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 108 - 108
12345